Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gozde Kar

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
The Journal of Clinical Investigation|July 6, 2021
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancerEvgenii N Tcyganov, Shino Hanabuchi, Ayumi Hashimoto, et al.
Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.
Cancer Discovery|September 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform TrialTina Cascone, Gozde Kar, Jonathan D Spicer, et al.
Nature Medicine|June 19, 2019
A cellular census of human lungs identifies novel cell states in health and in asthmaFelipe A Vieira Braga, Gozde Kar, Marijn Berg, et al.
Cancer Cell|July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerAna Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
The Journal of Clinical Investigation|July 6, 2021
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancerEvgenii N Tcyganov, Shino Hanabuchi, Ayumi Hashimoto, et al.
Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.
Cancer Discovery|September 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform TrialTina Cascone, Gozde Kar, Jonathan D Spicer, et al.
Nature Medicine|June 19, 2019
A cellular census of human lungs identifies novel cell states in health and in asthmaFelipe A Vieira Braga, Gozde Kar, Marijn Berg, et al.
Cancer Cell|July 11, 2025
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerAna Galan-Cobo, Natalie I Vokes, Yu Qian, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 3